Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update

First-in-class immune-stimulating antibody conjugate BDC-4182 in Phase 1 dose escalation study, initial clinical data expected in 3Q 2026 Cash ...

Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Initial clinical data for CLN-978 in SLE and RA confirmed for Q2 2026; repeat dosing data in RA confirmed for Q3 2026Zipalertinib rolling NDA ...

Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

KOMODO-1 first-in-human clinical trial of BBI-940 open for enrollment $108 million in cash provides runway into the second half of 2028, through expected clinical proof-of-concept readout for KOMODO-1 ...

Multi-Organization Partnership Announces $2.5 Million for Aging & Cancer Research

Taking aim at the leading risk factor for cancer, The Mark Foundation for Cancer Research and the Samuel Waxman Cancer Research Foundation (SWCRF) today announced $2.5 million to support science at ...

Voyager Acquisition Corp.: Voyager Acquisition Corporation Announces Redemption Results in Connection with its Business Combination with VERAXA Biotech AG

Voyager Acquisition Corporation (NASDAQ: "VACHU," "VACH," "VACHW") ("Voyager" or the "Company") today announced that holders of 25,217,315 of the Company's ...